An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax-Reference-Cited by-同舟云学术

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax

Published:2013-05-07 Issue:9 Volume:40 Page:1312-1320
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Itti Emmanuel,Meignan Michel,Berriolo-Riedinger Alina,Biggi Alberto,Cashen Amanda F.,Véra Pierre,Tilly Hervé,Siegel Barry A.,Gallamini Andrea,Casasnovas René-Olivier,Haioun Corinne

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-013-2435-6.pdf

Reference25 articles.

1. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906–14.

2. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging. 2003;30 Suppl 1:S97–105.

3. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50 Suppl 1:21S–30.

4. Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28:1896–903.

5. Juweid ME, Smith B, Itti E, Meignan M. Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma? J Clin Oncol. 2010;28:e719–20.

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy;Cancer Medicine;2024-03

2. [18F]FDG PET radiomics score generated by cross-combination approach for treatment response and prognosis prediction in primary gastrointestinal diffuse large B-cell lymphoma patients;2023-12-12

3. Nuclear medicine techniques in paediatric body oncology: Present and future;EJC Paediatric Oncology;2023-12

4. A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation;Tomography;2023-10-17

5. Validation of the ΔSUV_maxfor Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial;Journal of Nuclear Medicine;2023-09-21